ACA Repeal and How Trump Voters in Kentucky Threw Themselves Under the GOP Bus

by Nomad

The general interest news site, Vox, went to Whitley County, Kentucky to ask the residents there what they thought of Obamacare.
They were not at all happy.
So it's no surprise that these people overwhelmingly voted for Donald Trump. Throughout the campaign, the billionaire candidate made no secret of his vow to repeal the Affordable Care Act.

What is a surprise is that these Trump voters there are exactly the demographic that benefits the most from Obama's signature healthcare plan. Logically, they ought to be shooting off fireworks for Obamacare. They have the most to lose if Trump keeps his campaign promise about the repeal.

Vox attempts to learn what gives. How and why could voters vote against their own best interests on something as serious as health insurance?
The answers might surprise you.The video's worth watching.

A Snapshot from the Frontline: Where Boston's Homeless Find Health Care

by Nomad

Providing health care to homeless citizens is a job that gets far too little attention compared with, say, celebrity news. One film takes a closer look at the people who have dedicated themselves to that task.

Director  Jeff Schwartz hadn't anticipated that his short film would turn into a full-length documentary.. or a life-changing experience.

"With a small crew and unprecedented access to homeless men and women on the streets.. I was introduced to people I would have normally passed by. "

The result was a film that hat NPR has called "extremely powerful" and "fascinating."

"Give me a Shot of Anything: House Calls to the Homeless" deals with lives of homeless and the doctors and care-givers who provide them with health care. 

Schwartz gave his assessment:

"These are people that care. They see the humanity of the homeless and make sure they are granted basic rights like food, shelter and quality health care."

On a larger scale this film documents one city's response to America's health care needs, the Boston Healthcare for the Homeless Program. 

Cure for Hepatitis C: The Politics and Profits behind a Breakthrough

by Nomad

A breakthrough in curing a silent killer, Hepatitis C, should mean that patients will have a new lease on life. But unless they are extraordinarily wealthy or they  live in a state that expanded Medicaid in the wake of the Affordable Care Act, these people will be at the mercy of the profit-driven free market. So for most of the uninsured or under-insured Americans, it will mean no cure at all.

Good News 

Even for researchers who are loathe to use the word "cure," there's no question that the news is very good,

The Denver Post is reporting of a breakthrough drug for hepatitis C in clinical trials at the University of Colorado Hospital. This new anti-viral is being called the blockbuster cure for patients who have long had to endure debilitating treatment for this liver-destroying disease.

Astoundingly, Sovaldi, a daily-dose pill manufactured by California-based Gilead Sciences Inc., has cured about 90 percent of patients in only 12 weeks when used with older drugs, studies nationwide have found.

In other words, it's a very nearly the cure for a killer. Not life-long treatment like the HIV drug therapy, but an actual eradication of the affliction. 

A big big deal.

Silent Killer of the Baby Boomers
This is a disease that infects an estimated 150–200 million people around the world. In the US the majority of the estimated 3.2 million people with chronic hepatitis C virus (HCV) are baby boomer adults. Seventy-three percent of hepatitis C deaths were reported among those 45 to 64 years old.
For every 100 people who contract the virus, 75 will develop chronic infection. About 5 to 20 will develop cirrhosis over the next 20 to 30 years. Between 1 and 5 will die of cirrhosis and liver cancer. Meaning, more than 350 000 people die every year from hepatitis C-related liver diseases. The disease is found worldwide with some countries having chronic infection rates as high as 5% and above.

One of the particularly dangerous aspects of the disease is its insidious nature. Most of those infected with the virus do not know that they have it, which means they could easily be spreading it to others via exposure to blood—or, occasionally, sexual contact. The main mode of transmission in countries with infection rates above 5% is attributed to unsafe injections using contaminated equipment.

"In almost every country it is a significant public health problem, points out Charles Gore, president of the World Hepatitis Alliance, "and, in some, such as Egypt, which has 10% to 15% of its population living with hepatitis C, and Vietnam, where the prevalence of hepatitis B is 15% to 20%, it is simply overwhelming."

So curing this disease is unquestionably a great triumph for science. It's something that the researchers should be proud of. 

There is however one problem.

Now...The Bad News

Sovaldi was approved by the Food and Drug Administration (FDA) last December, but it won't be cheap. Sovaldi costs $1,000 a day and that adds up to staggering $84,000 for a 12-week supply.